Business
OncBioMune Submits Documents Necessary to Commercialize Norepinefrine for Low Blood Pressure and Heart Failure in Mexico
OncBioMune Submits Documents Necessary to Commercialize Norepinefrine for Low Blood Pressure and Heart Failure in Mexico.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nOncBioMune Submits Documents Necessary to Commercialize Norepinefrine for Low Blood Pressure and Heart Failure in Mexico\n\nOncBioMune Submits Documents Necessary to Commercialize Norepinefrine for Low Blood Pressure and Heart Failure in Mexico\n\nBATON ROUGE, LA--(Marketwired - August 22, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a revenue-stage biopharmaceutical company engaged in the development of targeted cancer therapies, a proprietary cancer vaccine technology and commercialization of a portfolio of products internationally, today reports that the requisite documents for transferring the Mexican rights to market Norepinefrine across the country to OncBioMune have been submitted to the Mexican Ministry of Health. On June 19, 2017, the Company announced acquiring the sanitary registration and intellectual property rights to Norepinefrine in Mexico and other markets from the Mexican subsidiary of the world's biggest generic drug company.Norepinefrine is approved in Mexico as indicated for the treatment of low blood pressure and heart failure. The Norepinefrine registration can also be used in other Central and Latin American countries. OncBioMune continues to conduct its due diligence on the most attractive markets, with plans to selectively launch the drug in other markets in the future.OncBioMune is presently negotiating details to bring Norepinefrine manufacturing to a state-of-the-art facility in Latin America, a move that will contain costs and provide the Company greater control in the supply chain.\"We estimate that the government bid/tender process will result in approximately US$1 million in annual sales, a solid addition to our growing portfolio of drugs in Mexico,\" commented Andrew Kucharchuk, President and Chief Financial Officer at OncBioMune. \"We don't foresee any issues with the transfer, which typically takes 60 days or less, which is keeping us right on track to have Norepinefrine generating revenue for us in 2018, at which time we'll make decisions about expansion into other promising markets.\"Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/. About OncBioMune Pharmaceuticals, Inc.OncBioMune Pharmaceuticals is a revenue-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, including ...